Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Navitoclax Shows Early Signs of Clinical Benefit in Myelofibrosis

April 1st 2021

The combination of navitoclax and ruxolitinib simultaneously inhibits 2 key mechanisms that promote myelofibrosis, resulting in an improvement in symptom control and positive changes in response biomarkers in patients with high-risk disease.

Rolling Submission Completed for Pacritinib for Myelofibrosis With Severe Thrombocytopenia

March 31st 2021

The rolling submission of a new drug application has been completed and submitted to the FDA to support the approval of pacritinib as a treatment for patients with myelofibrosis and severe thrombocytopenia defined as having platelet counts less than 50 x 109/L.

COMFORT Data and Ruxolitinib in Myelofibrosis

March 31st 2021

A review of data from the COMFORT trials and the management and real-world use of ruxolitinib in patients with myelofibrosis, also touching on its use during the coronavirus pandemic.

A Look at Fedratinib and the JAKARTA Trials

March 31st 2021

Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice.

Dr. Abu-Zeinah on the Efficacy of Interferon-Alpha in Polycythemia Vera

March 30th 2021

Ghaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.

Risk, Prognosis, and Nontransplant Options in Primary Myelofibrosis

March 24th 2021

Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.

Goals in Treating Low-Risk Primary Myelofibrosis

March 24th 2021

Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic.

Emerging Therapeutic Options in Polycythemia Vera

March 17th 2021

What to look forward to in the polycythemia vera space, including new clinical trials.

Real-World Use of Ruxolitinib in Polycythemia Vera

March 17th 2021

Experts give real-world insight in using ruxolitinib in patients with polycythemia vera.

FDA Issues Complete Response Letter for Ropeginterferon Alfa-2b for Polycythemia Vera

March 15th 2021

The FDA has issued a complete response letter regarding the biologics license application for ropeginterferon alfa-2b-njft for the treatment of patients with polycythemia vera.

Polycythemia Vera: An Update on Clinical Trials

March 10th 2021

Experts discuss clinical trial updates in polycythemia vera, including data from RESPONSE, RESPONSE-2, an international observational study of ruxolitinib, and REVEAL.

PV Progression and Guideline-Directed Management

March 10th 2021

Ruben A. Mesa, MD, highlights signs of disease progression and the utilization of guideline recommendations in the occurrence of a thrombotic event when treating polycythemia vera.

Interferon-Alpha Improves MFS and OS Over Standard Approaches in Polycythemia Vera

March 9th 2021

Interferon-alpha has been shown to significantly improve both myelofibrosis-free survival and overall survival over hydroxyurea and phlebotomy only in patients with polycythemia vera.

Approaches Abound for Managing Symptoms Associated With Myelofibrosis

March 4th 2021

Srdan Verstovsek, MD, PhD, shares recommendation updates for myelofibrosis treatment and emerging options under exploration to effectively manage disease-related symptoms.

Targeted DNA Sequencing Informs Posttransplant Relapse Rates in MDS

March 3rd 2021

Targeted DNA sequencing prior to transplant can be used to determine which patients with myelodysplastic syndrome are at high risk for posttransplant relapse and should forego reduced-intensity conditioning in lieu of myeloablative conditioning.

Therapeutic Considerations in Polycythemia Vera

March 3rd 2021

Key opinion leaders discuss treatment goals, considerations, and guideline recommendations for patients with low- or high-risk polycythemia vera.

Diagnosis and Evaluation in Polycythemia Vera

March 3rd 2021

Evaluating treatment, diagnostic criteria, and risk-assessment tools in polycythemia vera.

Novel Concepts to Improve Survival, Manage Associated Symptoms in Myelofibrosis

March 2nd 2021

Several novel therapeutics such as JAK inhibitors and luspatercept have been developed for the treatment of patients with myelofibrosis and its associated symptoms, paving the way for improved survival rates and new combination strategies over the last decade.

An Overview of Myeloproliferative Neoplasms

February 26th 2021

Srdan Verstovsek, MD, PhD, provides an overview of the similarities and differences between myeloproliferative neoplasms, including polycythemia vera, myelofibrosis, and essential thrombocythemia.

Individualizing Treatment Approaches in MPN

February 26th 2021

Experts provide insight on therapeutic approaches of myeloproliferative neoplasms, highlighting clinical trial data and disease characteristics of polycythemia vera, primary myelofibrosis, and essential thrombocythemia.